January 27, 2014
National Institute for Health and Care Excellence (NICE)
- Dapagliflozin in combination therapy for treating type 2 diabetes.
- Mirabegron for treating symptoms of overactive bladder.
- Pegloticase for treating severe debilitating chronic tophaceous gout.
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism.
- Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis.
No hay comentarios:
Publicar un comentario